Above the 40 (February 2, 2018) – Janet Yellen Exits As Oversold Market Conditions Loom

AT40 = 38.3% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 54.7% of stocks are trading above their respective 200DMAs VIX = 17.3 (28.5% increase!) Short-term Trading Call: bullish Commentary “We cannot tolerate pervasive and persistent misconduct at any bank and the consumers harmed by Wells Fargo expect that robust … Read more

Above the 40 (January 30, 2018) – The S&P 500 Trips Over the Volatility Speedbump

AT40 = 55.9% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 60.6% of stocks are trading above their respective 200DMAs VIX = 14.8 Short-term Trading Call: bullish Commentary Last Friday, the S&P 500 (SPY) rolled over a volatile dollar on its way to another all-time high. The volatility index, the … Read more

Above the 40 (January 17, 2018) – The S&P 500 Invalidates Its Reversal But Not Cleanly

AT40 = 66.3% of stocks are trading above their respective 40-day moving averages (DMAs) – Day #1 of an overbought period AT200 = 63.6% of stocks are trading above their respective 200DMAs VIX = 11.9 Short-term Trading Call: bullish Commentary The S&P 500 (SPY) made a resounding comeback from the previous day’s reversal. The move … Read more

Above the 40 (January 11, 2017) – A Market Soaring Back to the Edge of Overbought

AT40 = 69.0% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 63.3% of stocks are trading above their respective 200DMAs VIX = 9.9 Short-term Trading Call: cautiously bullish Commentary Last week, I complained about the stock market’s “rubber band” getting stretched. I claimed that AT40 (T2108), the percentage of stocks … Read more

Above the 40 (January 5, 2018) – The S&P 500 Rubberband Stretches Further

AT40 = 67.5% of stocks are trading above their respective 40-day moving averages (DMAs) AT200 = 63.2% of stocks are trading above their respective 200DMAs VIX = 9.2 Short-term Trading Call: cautiously bullish Commentary In my last Above the 40 I complained that market breadth was once again suffering thanks to an S&P 500 (SPY) … Read more

The Speculations of Morgan Stanley

The raging bull market has helped facilitate instant excitement any time a company announces a cryptocurrency-related project or product. Xunlei Limited (XNET) is one of several companies that have enjoyed such a boost. XNET soared from just over $4 to $25 in less than two months on the heels of crypto-news. Source for charts: FreeStockCharts.com … Read more

Above the 40 (October 6, 2017) – Stock Market Lift-Off

AT40 = 73.8% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #7 AT200 = 59.7% of stocks are trading above their respective 200DMAs VIX = 9.7 Short-term Trading Call: bullish Commentary This is what a lift-off for an extended overbought rally looks like. The S&P 500 (SPY) followed its … Read more

The Danger in DexCom…and the Opportunity

DexCom (DXCM) is a maker of continuous glucose monitoring (CGM) systems. Last week, the stock of the company cratered after Abbott Laboratories (ABT) received FDA approval of its competing FreeStyle Libre flash CGM. It is the first system that allows diabetics to check and monitor glucose levels without sticking themselves. In response to the news, … Read more

Above the 40 (September 29, 2017) – Stock Market Powers Up for A Potential Overbought Rally

AT40 = 71.3% of stocks are trading above their respective 40-day moving averages (DMAs) – overbought day #2 AT200 = 58.6% of stocks are trading above their respective 200DMAs VIX = 9.5 Short-term Trading Call: bullish Commentary It looks like an overbought rally is truly underway. AT40 (T2108), the percentage of stocks closing above their … Read more

Axovant Sciences: Betting On An Improved Risk Profile

I took immediate notice when Axovant Sciences (AXON) went public back in late 2015. The promise of a treatment for Alzheimer’s was a huge opportunity, and I immediately had thoughts of my grandfather who struggled with the disease for years before he passed away with a heart attack. Yet, AXON had no revenues and no … Read more